I wanted to turn your attention to two significant recent studies on Paxlovid, the Covid-19 oral pill that the U.S. government spent $12.6 billion taxpayer dollars on subsidizing for Pfizer.
The first study, which is brought to you by Pfizer funds (though they noticeably don’t use the brand name Paxlovid in the study), finds that Paxlovid does not actually work. They’ve known this since July, 2022, but for reasons unknown, waited two years to publish the results.
“The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir (Paxlovid) and those who received placebo,” the authors write in this New England Journal of Medicine study, which was published on April 3rd.
That’s right. It doesn’t work at all.
In rolling out Paxlovid, Pfizer claimed in a press release that its preliminary data showed an 89% reduction in hospitalization and death for patients who took the pill.
Curiously, the Pfizer-funded study concluded in July 2022, just months after Paxlovid became available, but this seems to be the first time that results have been public.
Hellbound and Down 